BioAge Labs (BIOA) Non-Current Deffered Revenue (2024 - 2025)
BioAge Labs' (BIOA) quarterly Non-Current Deffered Revenue came in at $556000.0 in Q3 2025, down 70.77% quarter-over-quarter from $1.9 million in Q2 2025.
BioAge Labs (BIOA) Non-Current Deffered Revenue (2024 - 2025) Analysis & Trends
BioAge Labs has disclosed Non-Current Deffered Revenue across 2 years of filings, most recently posting $556000.0 for Q3 2025.
- Non-Current Deffered Revenue for Q3 2025 came in at $556000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $556000.0 (changed N/A YoY), and the FY2024 annual result was $4.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue came in at $556000.0 for Q3 2025 at BioAge Labs, down from $1.9 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $4.7 million in Q4 2024 to a low of $556000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | BioAge Labs | 671.19 Mn | 288.00 Mn | -10.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 556,000.00 |
| Jun 30, 2025 | 1.90 Mn |
| Mar 31, 2025 | 3.23 Mn |
| Dec 31, 2024 | 4.67 Mn |